)
Visual
test
Kyntra Bio
Kyntra Bio (KYNB) investor relations material
Kyntra Bio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Mar, 2026
Executive summary
Completed sale of FibroGen China to AstraZeneca for ~$220 million, repaid senior secured term loan, and rebranded as Kyntra Bio, extending cash runway into 2028.
Advanced FG-3246 (CD46-targeted ADC) and companion PET agent FG-3180 in mCRPC, with active phase II enrollment and interim results expected in the second half of 2026.
Progressed roxadustat for anemia in lower-risk MDS, submitted phase III protocol, received orphan drug designation, and secured FDA agreement on trial design.
Positive results from FG-3246 combination study with enzalutamide in mCRPC presented at ASCO GU 2026, supporting phase II design.
Cash, equivalents, investments, and receivables totaled $109.4M at year-end, supporting operations into 2028.
Financial highlights
Q4 2025 revenue was $1.3M, down from $3.1M in Q4 2024; full year 2025 revenue was $6.4M, down from $29.6M in 2024.
Q4 2025 net loss from continuing operations was $14.6M ($3.61/share), compared to $8.7M ($2.15/share) in Q4 2024.
Full year 2025 net loss from continuing operations was $58.2M ($14.40/share), improved from $153.1M ($38.26/share) in 2024.
R&D expenses for 2025 were $23.5M, down from $95.7M in 2024; SG&A expenses were $27.7M, down from $49.3M.
Gross margin for Q4 2025 was $1.0M on $1.3M revenue; operating loss for Q4 2025 was $13.5M, full year operating loss was $45.9M.
Outlook and guidance
Interim results from the phase II FG-3246 monotherapy trial expected in the second half of 2026; mature RPFS data anticipated in 2027.
Phase III trial for roxadustat in lower-risk MDS targeted to initiate in the second half of 2026, pending FDA feedback.
Costs for an internally run phase III LR-MDS study are not included in current cash runway projections.
Continued evaluation of internal development versus strategic partnership for roxadustat.
Impact of G-CSF on FG-3246 dose consistency
CD46 PET role in FG-3246 patient selection
Roxadustat competitive edge in RS-negative MDS
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kyntra Bio
- Lead oncology and MDS assets advance with key trial milestones and strong financial position.KYNB
Leerink Global Healthcare Conference 202611 Mar 2026 - Pipeline advances in prostate cancer and anemia, with strong cash position and late-stage catalysts.KYNBCorporate presentation11 Mar 2026
- Advancing CD46-targeted mCRPC and Phase III-ready MDS programs, with key data expected in 2024.KYNBOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- Q2 revenue up 14% as China roxadustat growth and cost cuts offset pamrevlumab exit.KYNBQ2 20242 Feb 2026
- Pivotal pancreatic cancer data, strong China sales, and oncology pipeline drive near-term outlook.KYNBGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- FG-3246 and PET46 advance in mCRPC as roxadustat drives growth and new partnerships emerge.KYNBH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Q3 revenue up 15%, China Roxadustat sales up 57%, but liquidity risks remain.KYNBQ3 202414 Jan 2026
- Pipeline advances in oncology and hematology, with strengthened financials after China sale.KYNBH.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025
- China sale for $160M funds U.S. oncology focus, extends runway, and advances lead assets.KYNBStatus Update26 Dec 2025
Next Kyntra Bio earnings date
Q1 20264 May, 2026
Kyntra Bio
Next Kyntra Bio earnings date
Q1 20264 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage